Sesen Bio, Inc. SESN
At closeMar 7, 2023, 4:00 PM EST
52-week range unavailable
- Market cap
- 127.96M
- Revenue (ttm)
- 40.00M
- Profit margin
- -49.71%
- Shares out
- 203.49M
- Forward P/E
- -1.05
- Volume
- 1.78M
- Open
- 0.5732
- Previous close
- 0.6288
- Day's range
- 0.57 – 0.6288
- Beta
- 0.83
- Analysts
- Hold
- Price target
- 12.00 (+1808.4%)
- Earnings date
- Feb 28, 2023
2Y -0.6412 (-50.49%)
Key statistics
- Enterprise value
- 2.39B
- PEG ratio
- 0.00
- Price / sales
- 3.20
- Price / book
- 0.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -100.00%
- Free cash flow
- 23.46M
- Total cash
- 166.92M
- Total debt
- 0
- Return on equity
- -12.06%
- Short % of float
- 1.05%
- 50-day average
- 0.59878
- 200-day average
- 0.617672
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 28, 2023
Expected Feb 28, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 28, 2023 | Dec 1, 2022 | -0.11 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.08 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.13 | — | — | — |
| May 9, 2022 | Mar 1, 2022 | -0.05 | — | — | — |
| Feb 28, 2022 | Dec 1, 2021 | -0.08 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | -0.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Feb 17, 2021 | Canaccord Genuity | main | — | Buy |
| Feb 17, 2021 | HC Wainwright & Co. | main | — | Buy |
| Jun 11, 2019 | H.C. Wainwright | up | Neutral | Buy |
| Jul 23, 2018 | Jefferies | init | — | Buy |
About Sesen Bio, Inc.
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sesenbio.com
News
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics - Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results 
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results 
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma 
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma 
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting 
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting 
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger 
BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
Your note
Sign in to keep a note on SESN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOURDOW CARRIE L | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| CANNELL THOMAS R | Chief Executive Officer | Sale | Mar 1, 2023 | 672,386 |
| DUKER JAY S | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| FORBES MONICA | Chief Financial Officer | Sale | Mar 1, 2023 | 505,664 |
| HONIG PETER K | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| JEWETT MICHAEL A.S. M.D. | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 5.33% | 10,854,300 | 6.83M | Dec 30, 2022 |
| Bml Capital Management, LLC | 4.04% | 8,227,969 | 5.17M | Dec 30, 2022 |
| Blackrock Inc. | 1.29% | 2,633,452 | 1.66M | Dec 30, 2022 |
| Geode Capital Management, LLC | 1.13% | 2,294,948 | 1.44M | Dec 30, 2022 |
| Millennium Management Llc | 0.51% | 1,035,151 | 650.90K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.50% | 1,018,956 | 640.72K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 6,362,488 | 4.00M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.32% | 2,667,125 | 1.68M | Sep 29, 2022 |
| Vanguard Explorer Fund, Inc. | 0.73% | 1,476,709 | 928.55K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.50% | 1,023,195 | 643.38K | Nov 29, 2022 |
| Fidelity NASDAQ Composite Index ETF | 0.22% | 438,675 | 275.84K | Dec 30, 2022 |
| Fidelity Small Cap Enhanced Index Fund | 0.15% | 304,482 | 191.46K | Nov 29, 2022 |